The research of Kate Lawrenson, PhD, focuses on the role of the non-coding genome in the biology of and susceptibility to ovarian cancer. Her lab uses novel subtype-specific in vitro and in vivo models of ovarian cancer to elucidate the function of candidate susceptibility variants and their target genes, coupled with state-of-the-art next generation sequencing-based methodologies to characterize the ovarian cancer genome, transcriptome and epigenome. The overarching aim of Lawrenson's research is to identify new markers and targets that could ultimately be used clinically to reduce morbidity and mortality associated with ovarian carcinoma.

• Undergraduate: University College London, 2005
• Doctorate: University College London, 2010

• Cancer Institute (Samuel Oschin Comprehensive Cancer Institute)
• Women's Cancer Program
• Cancer
• Obstetrics and Gynecology

• Keleman LE, Lawrenson K, Tyrer J, Lee JM, Li Q, Seo J, Phelan CP, Beesley J, Chen X, Spindler T,et al. Identification and functional analysis of risk variants for mucinous ovarian cancer. Nat Genet. 2015;47(8):888-897.
• Coetzee S, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Rhie SK, Karst A, Drapkin R, Karaven R, et al. Regulatory profiling of ovarian cancer precursor tissues and functional annotation of cancer susceptibility loci. Hum Mol Genet. 2015;24.
• Lawrenson K, Grun B, Gayther SA. Heterotypic three-dimensional in vitro modeling of stromal-epithelial interactions during ovarian cancer initiation and progression. J Vis Exp. 2012;(66):e4206.